Cabot (CBT)
(Delayed Data from NYSE)
$104.24 USD
+2.86 (2.82%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $104.35 +0.11 (0.11%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$104.24 USD
+2.86 (2.82%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $104.35 +0.11 (0.11%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth A Momentum A VGM
Zacks News
Cabot (CBT) Earnings & Revenues Surpass Estimates in Q1
by Zacks Equity Research
Solid segment performances contributed to Cabot's (CBT) results in Q1.
Chemical Stock Earnings to Watch on Feb 6: AXTA, CBT & More
by Zacks Equity Research
Most of the chemical stocks reporting earnings on Feb 6 are unlikely to impress.
Why Cabot Corp. (CBT) Might Surprise This Earnings Season
by Zacks Equity Research
Cabot (CBT) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Is a Beat in the Cards for Cabot Corp (CBT) in Q1 Earnings?
by Zacks Equity Research
Growth-focused investments are likely to support Cabot Corp's (CBT) earnings in Q1.
4 Chemical Stocks Well Poised to Trump Earnings Estimates
by Zacks Equity Research
Chemical makers continue to see strong demand from construction and automotive sectors - major chemical end-use markets.
Cabot Corp (CBT) Q4 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Cabot (CBT) reported a year-over-year decrease in adjusted earnings for fiscal fourth quarter that missed the Zacks Consensus Estimate.
Mosaic's (MOS) Earnings and Revenues Top Estimates in Q3
by Zacks Equity Research
Strong operational performance and better price realization boosted Mosaic's (MOS) bottom line in Q3.
Will Higher Shipments Drive WestRock (WRK) Q4 Earnings?
by Zacks Equity Research
WestRock's (WRK) fourth-quarter fiscal 2017 results will benefit from seasonally higher volumes, sales price increases, favorable mix and productivity. However, higher input costs will dent results.
Can CVR Partners (UAN) Spring a Surprise in Q3 Earnings?
by Zacks Equity Research
Weak nitrogen prices are likely to dent CVR Partners' (UAN) earnings in Q3.
Goldcorp's (GG) Q3 Earnings In Line, Revenues Miss Estimates
by Zacks Equity Research
Strong operating performance at Cerro Negro and Penasquito drives Goldcorp's (GG) third-quarter 2017 earnings.
Agnico-Eagle (AEM) Q3 Earnings Top, Ups Production Outlook
by Zacks Equity Research
Record gold production and strong cash flow drives Agnico-Eagle's (AEM) Q3 performance.
Should You Buy Cabot Corporation (CBT) Ahead of Earnings?
by Zacks Equity Research
Cabot Corporation (CBT) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Is a Beat in the Cards for Cabot Corp (CBT) in Q4 Earnings?
by Zacks Equity Research
Cabot Corp's (CBT) fourth-quarter fiscal 2017 earnings are expected to gain from higher volumes across performance chemicals' end markets and lower fixed costs in purification solutions.
4 Chemical Stocks Well Poised to Top Earnings Estimates
by Zacks Equity Research
The chemical industry has so far enjoyed a positive run this year.
Freeport (FCX) Tops Earnings, Revenue Estimates in Q3
by Zacks Equity Research
Freeport's (FCX) adjusted earnings of 36 cents in third-quarter 2017 beat the Zacks Consensus Estimate of 29 cents. The company gained from higher copper prices and its cost management actions.
BHP Billiton Reports Q1 Operational Results, Reaffirms View
by Zacks Equity Research
BHP Billiton's first-quarter fiscal 2018 iron-ore output dipped 3%. The company reaffirmed the productivity guidance for fiscal 2018.
Should Value Investors Pick Cabot Corporation (CBT) Stock Now?
by Zacks Equity Research
Let's put Cabot Corporation (CBT) stock into this equation and find out if it is a good choice for value-oriented investors right now.
Cabot Corp (CBT) Q3 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Strong performance in Reinforcement Materials segment boosted sales growth for Cabot Corp. (CBT) in the third quarter.
What's in the Cards for Cabot Corp (CBT) in Q3 Earnings?
by Zacks Equity Research
Cabot Corp.'s (CBT) third-quarter fiscal 2017 earnings are likely to gain from strong demand of Performance Chemicals' end markets amid higher feedstock costs.
Is Cabot a Great Stock for Value Investors?
by Zacks Equity Research
Let's focus on Cabot Corporation (CBT) stock and find out if it is a good choice for value-oriented investors right now or not.
Cabot Corp (CBT) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Cabot Corporation (CBT) recorded net earnings of $74 million or $1.18 per share for the second quarter of fiscal 2017, compared with $48 million or 76 cents a year ago.
Chemical Stocks Earnings Roster for May 1: CC, CBT & IPHS
by Zacks Equity Research
We peek at three chemical companies that are slated to report quarterly results on May 1.
Can Cabot Corp (CBT) Pull a Surprise This Earnings Season?
by Zacks Equity Research
Specialty chemicals and performance materials producer, Cabot Corp. (CBT), is set to release second-quarter fiscal 2017 results after the market closes on May 1.
Albemarle (ALB) Tops Earnings, Revenue Estimates in Q4
by Zacks Equity Research
Albemarle's (ALB) fourth-quarter earnings and sales topped the respective Zacks Consensus Estimate.
Chemical Stocks' Earnings Slated on Feb 1: CE, CBT, OMN
by Zacks Equity Research
We take a look at three chemical companies that are slated to report their quarterly results on Feb 1.